NeoGenomics, Inc. (NASDAQ:NEO) Stake Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 10.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 566,754 shares of the medical research company’s stock after buying an additional 52,594 shares during the period. Charles Schwab Investment Management Inc. owned 0.59% of NeoGenomics worth $12,435,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Commonwealth Equity Services LLC lifted its holdings in NeoGenomics by 3.8% during the second quarter. Commonwealth Equity Services LLC now owns 25,647 shares of the medical research company’s stock valued at $562,000 after purchasing an additional 945 shares in the last quarter. Prudential Financial Inc. lifted its holdings in NeoGenomics by 8.1% during the second quarter. Prudential Financial Inc. now owns 163,570 shares of the medical research company’s stock valued at $3,589,000 after purchasing an additional 12,250 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in NeoGenomics by 33.7% during the second quarter. Envestnet Asset Management Inc. now owns 36,908 shares of the medical research company’s stock valued at $810,000 after purchasing an additional 9,309 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in NeoGenomics by 122.4% during the second quarter. Wells Fargo & Company MN now owns 532,393 shares of the medical research company’s stock valued at $11,680,000 after purchasing an additional 293,049 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in NeoGenomics during the first quarter valued at $664,000. 84.84% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have issued reports on NEO shares. Leerink Swann set a $30.00 price objective on shares of NeoGenomics and gave the company a “buy” rating in a report on Wednesday, July 31st. ValuEngine downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Benchmark set a $27.00 price target on shares of NeoGenomics and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Needham & Company LLC set a $27.00 price target on shares of NeoGenomics and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, Raymond James raised their price target on shares of NeoGenomics from $23.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 31st. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $24.75.

NeoGenomics stock traded up $0.08 during midday trading on Friday, hitting $19.73. 428,296 shares of the stock were exchanged, compared to its average volume of 1,019,543. NeoGenomics, Inc. has a fifty-two week low of $11.05 and a fifty-two week high of $26.89. The stock has a market capitalization of $2.03 billion, a price-to-earnings ratio of 151.77 and a beta of 0.92. The stock’s 50-day simple moving average is $22.09 and its 200 day simple moving average is $22.43. The company has a current ratio of 4.67, a quick ratio of 4.52 and a debt-to-equity ratio of 0.25.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings results on Tuesday, July 30th. The medical research company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. The business had revenue of $101.71 million during the quarter, compared to analysts’ expectations of $97.32 million. During the same period last year, the business earned $0.05 earnings per share. The business’s revenue for the quarter was up 50.1% on a year-over-year basis. Equities analysts anticipate that NeoGenomics, Inc. will post 0.19 EPS for the current fiscal year.

In related news, Director Steven C. Jones sold 181,339 shares of NeoGenomics stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $24.92, for a total value of $4,518,967.88. Following the completion of the transaction, the director now owns 245,234 shares in the company, valued at $6,111,231.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven C. Jones sold 40,737 shares of NeoGenomics stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $25.02, for a total transaction of $1,019,239.74. Following the completion of the transaction, the director now owns 245,234 shares of the company’s stock, valued at approximately $6,135,754.68. The disclosure for this sale can be found here. Insiders sold 241,370 shares of company stock valued at $6,017,680 in the last 90 days. Company insiders own 8.80% of the company’s stock.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Story: Short Selling

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.